Antimicrobial Agents Practice Questions

Q: Which fluoroquinolone is associated with fatal hypoglycemia?

Gatifloxacin. **Explanation:** **Gatifloxacin** is the correct answer because it is uniquely associated with severe dysglycemias (both hypoglycemia and hyperglycemia). The underlying mechanism involves the blockade of **ATP-sensitive potassium channels** in pancreatic beta cells. This leads to excessive insulin release (causing fatal hypoglycemia) or, in some cases, inhibition of insulin synthesis (causing hyperglycemia). Due to these life-threatening metabolic side effects, systemic use of Gatifloxacin was withdrawn globally, though it remains available as an ophthalmic preparation. **Analysis of Incorrect Options:** * **Lomefloxacin:** Primarily known for causing significant **phototoxicity** (photosensitivity reactions) and is rarely used due to this profile. * **Sparfloxacin:** Also associated with severe phototoxicity and is notorious for causing **QT interval prolongation**, leading to a risk of Torsades de Pointes. * **Trovafloxacin:** Withdrawn from general use due to severe, unpredictable **hepatotoxicity** (liver failure), though it was once a potent fourth-generation agent. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Fluoroquinolone Toxicity:** * **G**atifloxacin = **G**lucose (Dysglycemia) * **S**parfloxacin = **S**unlight (Phototoxicity) & **S**low heart (QT prolongation) * **T**rovafloxacin = **T**oxic liver (Hepatotoxicity) * **General Side Effects:** Tendon rupture and tendinitis (especially Achilles tendon) are class-wide warnings for fluoroquinolones, particularly in the elderly or those on steroids. * **Contraindication:** They are generally avoided in children and pregnancy due to potential **cartilage damage** (arthropathy).

Q: What are the known complications of Zidovudine therapy?

All of the above. **Explanation:** Zidovudine (AZT) is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) used in the management of HIV/AIDS. Its side effect profile is a high-yield topic for NEET-PG, primarily revolving around its impact on mitochondrial DNA polymerase-gamma and bone marrow suppression. 1. **Anemia (Option B):** This is the most characteristic and dose-limiting toxicity of Zidovudine. It causes **macrocytic anemia** and neutropenia due to direct bone marrow suppression. In clinical practice, a rising Mean Corpuscular Volume (MCV) is often used as a marker of patient compliance with Zidovudine. 2. **Nausea and Vomiting (Option A):** Gastrointestinal intolerance is the most common early side effect. While usually self-limiting, it occurs in a significant percentage of patients starting therapy. 3. **Steatosis (Option C):** As an NRTI, Zidovudine can cause mitochondrial toxicity. This leads to impaired fatty acid oxidation in the liver, resulting in **hepatic steatosis** (fatty liver), which may progress to potentially fatal lactic acidosis. **Why "All of the above" is correct:** Since Zidovudine causes systemic effects ranging from acute GI distress to chronic hematological and metabolic complications, all listed options are recognized adverse effects. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Zidovudine:** "Z" for **Z**apped bone marrow (Anemia/Neutropenia). * **L-Carnitine:** Sometimes used to manage NRTI-induced mitochondrial toxicity. * **Drug of Choice:** Zidovudine is the preferred drug for preventing **vertical transmission** (mother-to-child) of HIV during pregnancy and labor. * **Avoid Co-administration:** Do not give Zidovudine with **Stavudine (d4T)** as they compete for the same phosphorylation pathway (antagonistic effect).

Q: What is the recommended treatment for CMV retinitis in an AIDS patient?

Valganciclovir. **Explanation:** **Cytomegalovirus (CMV) retinitis** is the most common opportunistic ocular infection in patients with AIDS (typically when CD4 counts fall below 50 cells/mm³). **Why Valganciclovir is correct:** Valganciclovir is the **L-valyl ester prodrug of Ganciclovir**. It has excellent oral bioavailability and is considered the **first-line treatment** for both the induction and maintenance phases of CMV retinitis. Once ingested, it is rapidly converted to ganciclovir, which inhibits viral DNA polymerase. Its oral administration makes it superior to intravenous ganciclovir for long-term management, providing comparable efficacy with less procedural morbidity. **Why the other options are incorrect:** * **Amantadine:** An anti-influenza agent that inhibits the M2 ion channel. It is used for Influenza A and as an adjunct in Parkinson’s disease, but has no activity against CMV. * **Fludarabine:** A purine analog used as a chemotherapy agent (antimetabolite) primarily for Chronic Lymphocytic Leukemia (CLL). It is not an antiviral. * **Oseltamivir:** A neuraminidase inhibitor used for the treatment and prophylaxis of Influenza A and B. It does not inhibit DNA viruses like CMV. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Valganciclovir (Oral) or Ganciclovir (IV). * **Alternative for Resistant CMV:** **Foscarnet** (pyrophosphate analog) or **Cidofovir**. * **Major Side Effect:** Ganciclovir/Valganciclovir causes **bone marrow suppression** (neutropenia). * **Drug Interaction:** Avoid co-administration of Ganciclovir with **Zidovudine (AZT)** due to additive myelosuppression. * **CMV Retinitis Appearance:** Classically described as "Pizza-pie" or "Crushed cheese and tomato" fundus.

Q: Which of the following drugs is NOT used in the treatment of Leishmaniasis?

Cyclosporine. **Explanation:** **1. Why Cyclosporine is the correct answer:** Cyclosporine is an **immunosuppressant** that acts as a calcineurin inhibitor. It is primarily used to prevent organ transplant rejection and treat autoimmune conditions (e.g., rheumatoid arthritis, psoriasis). It has **no anti-protozoal activity** and is not used to treat Leishmaniasis. In fact, because it suppresses T-cell immunity, it could potentially worsen an opportunistic infection like Leishmaniasis. **2. Why the other options are incorrect:** * **Ketoconazole (Option B):** This oral antifungal inhibits ergosterol synthesis in the *Leishmania* cell membrane. It is an alternative agent used specifically for **Cutaneous Leishmaniasis**. * **Pentamidine (Option C):** This is a second-line agent for **Visceral Leishmaniasis (Kala-azar)**. It interferes with the parasite's DNA synthesis and mitochondrial function. It is often used when primary treatments fail or are contraindicated. * **Amphotericin B (Option D):** This is currently the **drug of choice** for Visceral Leishmaniasis (especially the Liposomal formulation). It binds to ergosterol in the parasite membrane, creating pores that lead to cell death. **3. High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Liposomal Amphotericin B is the preferred treatment for Kala-azar due to high efficacy and lower toxicity compared to conventional forms. * **Miltefosine:** This is the **only oral drug** approved for the treatment of Visceral Leishmaniasis. * **Sodium Stibogluconate (Antimonials):** Historically the first-line treatment, but now limited by significant resistance (especially in Bihar, India) and cardiotoxicity (QT prolongation). * **Paromomycin:** An aminoglycoside antibiotic that is also effective against *Leishmania* when given intramuscularly.

Q: A 36-year-old woman recently treated for leukemia is admitted to the hospital with malaise, chills, and high fever. Gram stain of blood reveals the presence of gram-negative bacilli. The initial diagnosis is bacteremia, and parenteral antibiotics are indicated. The patient's record reveals a severe urticarial rash, hypotension, and respiratory difficulty after oral penicillin V about 6 months ago. What is the most appropriate antibiotic to administer?

Aztreonam. The patient presents with **Gram-negative bacteremia** and a history of **Type I hypersensitivity (anaphylaxis)** to penicillin, characterized by urticaria, hypotension, and respiratory distress. In such cases, cross-reactivity between beta-lactam antibiotics is a major clinical concern [1]. **Why Aztreonam is correct:** Aztreonam is a **Monobactam**. Its unique monocyclic beta-lactam ring structure prevents cross-reactivity with other beta-lactams (penicillins, cephalosporins, and carbapenems), making it the drug of choice for Gram-negative infections in penicillin-allergic patients [1]. It specifically binds to PBP-3 of aerobic Gram-negative bacteria (including *Pseudomonas*) and has no activity against Gram-positives or anaerobes [3]. **Why other options are incorrect:** * **Ampicillin/Sulbactam:** This is an aminopenicillin combination. It is strictly contraindicated due to the patient’s history of anaphylaxis to Penicillin V [1][3]. * **Cefazolin:** As a first-generation cephalosporin, it carries a significant risk of cross-reactivity (approx. 1-10%) in patients with IgE-mediated penicillin allergy [1]. * **Imipenem/Cilastatin:** Carbapenems share a common bicyclic nucleus with penicillins. While the cross-reactivity rate is lower than previously thought (~1%), it is still avoided in patients with documented history of anaphylaxis if safer alternatives like Aztreonam are available [1]. **NEET-PG High-Yield Pearls:** 1. **The Exception Rule:** Aztreonam does **not** cross-react with penicillins **EXCEPT** with **Ceftazidime**, because they share an identical side chain. 2. **Spectrum:** Aztreonam is often referred to as the "Gram-negative specialist" (similar spectrum to aminoglycosides but without nephrotoxicity) [2]. 3. **Anaphylaxis History:** If a question mentions "hypotension," "wheezing," or "laryngeal edema" after penicillin, avoid all beta-lactams except Monobactams [1].

Q: Which of the following drugs can cause cartilage damage in children?

Ciprofloxacin. ### Explanation **Correct Option: C. Ciprofloxacin** Ciprofloxacin belongs to the **Fluoroquinolone** class of antibiotics. The primary reason it is generally contraindicated in children (under 18 years) is its potential to cause **arthropathy** (cartilage damage). Experimental studies in juvenile animals have demonstrated that fluoroquinolones can cause permanent damage to the weight-bearing joints by inducing erosions in the articular cartilage. While clinical use in children is sometimes necessary for specific conditions (e.g., cystic fibrosis or complicated UTIs), it remains a high-yield contraindication for exams due to this risk of growth plate interference. **Analysis of Incorrect Options:** * **A. Cotrimoxazole:** This drug is primarily avoided in neonates because it competes with bilirubin for albumin binding sites, potentially leading to **kernicterus**. It does not affect cartilage. * **B. Penicillin:** These are among the safest antibiotics in the pediatric population. Their primary adverse effect is hypersensitivity (Type I IgE-mediated reactions), not musculoskeletal toxicity. * **C. Metronidazole:** Used for anaerobic infections and protozoal diseases, its main side effects include a metallic taste, disulfiram-like reaction with alcohol, and peripheral neuropathy with prolonged use. It has no known effect on cartilage. **Clinical Pearls for NEET-PG:** * **Fluoroquinolones & Tendons:** In adults, fluoroquinolones are associated with an increased risk of **tendonitis and Achilles tendon rupture**, especially in the elderly or those on corticosteroids. * **Mechanism of Action:** They inhibit **DNA Gyrase** (Gram-negative) and **Topoisomerase IV** (Gram-positive), preventing DNA supercoiling. * **Other Pediatric Contraindications:** Remember **Tetracyclines** are avoided in children <8 years due to permanent **tooth discoloration** and bone growth retardation.

Q: What is the recommended single dose of fosfomycin for a 40-year-old patient weighing 60 kg?

3 g. Fosfomycin is a unique bactericidal antibiotic that inhibits the first step of bacterial cell wall synthesis by inactivating the enzyme Enolpyruvate transferase (MurA). This prevents the formation of UDP-N-acetylmuramic acid, a precursor of peptidoglycan. 1. Why 3 g is correct: For the treatment of uncomplicated urinary tract infections (UTIs), specifically acute cystitis in women caused by susceptible strains of E. coli or Enterococcus faecalis, the standard FDA-approved and clinical guideline dosage is a single 3-gram oral dose. It is administered as granules dissolved in water. The drug achieves very high concentrations in the urine (up to 2000–4000 µg/mL) which remain above the MIC for most uropathogens for 24–48 hours, justifying the single-dose regimen. 2. Why other options are incorrect: 6 g (Option A): This is double the standard dose for uncomplicated UTI and is not a standard single-dose regimen. 6 mg/kg and 3 mg/kg (Options B & D): Fosfomycin dosing for UTIs is fixed, not weight-based. Weight-based dosing (mg/kg) is typically reserved for intravenous fosfomycin used in systemic or multidrug-resistant infections, but even then, the doses are significantly higher (e.g., 100–400 mg/kg/day). High-Yield Clinical Pearls for NEET-PG: Mechanism of Action: Inhibits MurA enzyme (Cell wall synthesis inhibitor). Spectrum: Broad-spectrum (Gram-positive and Gram-negative); notably effective against VRE (Vancomycin-Resistant Enterococci) and ESBL-producing organisms. Pregnancy: It is considered safe (Category B) and is often used for asymptomatic bacteriuria in pregnancy. Synergy: Often shows synergy when combined with Beta-lactams or Aminoglycosides.

Q: Isoniazid may show cross-resistance with which of the following anti-tubercular drugs?

Ethionamide. **Explanation:** The correct answer is **Ethionamide**. **Mechanism of Cross-Resistance:** The cross-resistance between Isoniazid (INH) and Ethionamide is rooted in their shared mechanism of action. Both drugs are **prodrugs** that inhibit **mycolic acid synthesis**, a vital component of the mycobacterial cell wall. * INH is activated by the enzyme **KatG** (catalase-peroxidase) and targets the **InhA** enzyme (enoyl-ACP reductase). * Ethionamide is activated by a different enzyme (**EthA**) but targets the **same InhA enzyme**. * **The Link:** Mutations in the **inhA gene** (promoter region) lead to overexpression of the InhA enzyme. Since both drugs target this specific enzyme, a mutation here results in **cross-resistance** between INH and Ethionamide. (Note: Mutations in the *katG* gene cause high-level resistance to INH only, without affecting Ethionamide). **Why Incorrect Options are Wrong:** * **Rifampicin:** Acts by inhibiting DNA-dependent RNA polymerase (*rpoB* gene mutation). It has a completely different target and activation pathway. * **Cycloserine:** A second-line drug that inhibits peptidoglycan synthesis by acting as an antimetabolite of D-alanine. * **Streptomycin:** An aminoglycoside that inhibits protein synthesis by binding to the 30S ribosomal subunit (*rpsL* or *rrs* gene mutations). **High-Yield Clinical Pearls for NEET-PG:** * **INH Resistance:** Most commonly due to *katG* gene mutation (high-level resistance) or *inhA* gene mutation (low-level resistance + cross-resistance with Ethionamide). * **Ethionamide Side Effects:** Notable for causing intense GI irritation and a metallic taste. * **Fast vs. Slow Acetylators:** INH metabolism depends on N-acetyltransferase 2 (NAT2). Slow acetylators are prone to peripheral neuropathy (prevented by **Pyridoxine/Vit B6**), while fast acetylators may show poor response.

Question 1

Which fluoroquinolone is associated with fatal hypoglycemia?

Accepted Answer

Gatifloxacin

Answer

Lomefloxacin

Answer

Sparfloxacin

Answer

Trovafloxacin

Question 2

What are the known complications of Zidovudine therapy?

Accepted Answer

All of the above

Answer

Nausea and vomiting

Answer

Anemia

Answer

Steatosis

Question 3

What is the recommended treatment for CMV retinitis in an AIDS patient?

Accepted Answer

Valganciclovir

Answer

Amantadine

Answer

Fludrabine

Answer

Oseltamivir

Question 4

Which of the following drugs is NOT used in the treatment of Leishmaniasis?

Accepted Answer

Cyclosporine

Answer

Ketoconazole

Answer

Pentamidine

Answer

Amphotericin B

Question 5

A 36-year-old woman recently treated for leukemia is admitted to the hospital with malaise, chills, and high fever. Gram stain of blood reveals the presence of gram-negative bacilli. The initial diagnosis is bacteremia, and parenteral antibiotics are indicated. The patient's record reveals a severe urticarial rash, hypotension, and respiratory difficulty after oral penicillin V about 6 months ago. What is the most appropriate antibiotic to administer?

Accepted Answer

Aztreonam

Answer

Ampicillin plus sulbactam

Answer

Cefazolin

Answer

Imipenem plus cilastatin

Question 6

Which of the following drugs can cause cartilage damage in children?

Accepted Answer

Ciprofloxacin

Answer

Cotrimoxazole

Answer

Penicillin

Answer

Metronidazole

Question 7

What is the recommended single dose of fosfomycin for a 40-year-old patient weighing 60 kg?

Accepted Answer

3 g

Answer

6 g

Answer

6 mg/kg

Answer

3 mg/kg

Question 8

All of the following are true about Penicillins except?

Accepted Answer

Benzathine penicillin is used in the treatment of neurosyphilis.

Answer

Penicillin V is acid stable and can be given orally.

Answer

Probenecid increases the duration of action of penicillins.

Answer

Penicillin V acts mainly on Gram-positive microorganisms.

Question 9

Isoniazid may show cross-resistance with which of the following anti-tubercular drugs?

Accepted Answer

Ethionamide

Answer

Rifampicin

Answer

Cycloserine

Answer

Streptomycin

Question 10

Which of the following best describes the mechanism of action of nucleoside/nucleotide analogs, such as didanosine, used in highly active antiretroviral therapy (HAART) for HIV patients?

Accepted Answer

They prematurely terminate the DNA synthesized by reverse transcriptase.

Answer

They prevent the hydrolysis of the viral polyprotein.

Answer

They directly bind to and inhibit reverse transcriptase.

Answer

They inhibit the synthesis of viral proteins.

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?